Rubius snaps up Novartis vet Pablo Cagnoni as CEO; MiMedx dumps two execs following internal investigation
→ David Epstein has recruited another fellow Novartis vet to Rubius Therapeutics, the cell therapy startup that he’s chairing — this time straight to the top job. New CEO Pablo Cagnoni joins Flagship Pioneering partner Torben Straight Nissen, who’s been leading the company as president. The Cambridge, MA-based company believes it can engineer red blood cells to transport proteins, instead of oxygen, needed to fight diseases. The applications span from cancer — which Cagnoni is intimately familiar with, first as an oncologist and then as an exec at Novartis oncology and Onyx Pharma — to autoimmune and rare diseases. With a preclinical biotech that’s eyeing a whole new class of therapies, Cagnoni has his work cut out for him, but thanks to a recently completed mega-round, he also has $220 million in the bank to help.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.